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INTRODUCTION
Dabigatran Etexilate (DE) (BIBR 1048) is a newly approved oral direct 
thrombin inhibitor which is indicated for anticoagulation therapy 
to reduce the risk of strokes and systemic embolism in patients with 
non-valvular atrial fibrillation. DE is marketed as “PRADAXA” in the 
form of DE Mesylate (DEM) (BIBR 1048 MS) salt as 75 mg, 110 mg, 
and 150 mg immediate release capsule. DE is ester prodrug, after oral 
administration, DE is rapidly absorbed and completely hydrolyzed to 
its active moiety, Dabigatran (BIBR 953), by non-specific abundant 
esterases in the gut, plasma, and liver. It is being studied for various 
clinical indications and in some cases it offers an alternative and 
beneficial as compare to warfarin as the preferred orally administered 
anticoagulant (“blood thinner”) because it does not require frequent 
monitoring of the clotting tendency of blood while offering similar 
results in terms of efficacy [1-4].
Chemically, DEM is a mesylate salt of a prodrug DE of which Dabigatran 
is an active therapeutic ingredient. DEM contains two ester functional 
groups (ethyl ester and etexilate ester). The di-ester is essentially a 
prodrug for the corresponding zwitterion, and the nomenclature and 
strength are based on the relevant di-ester, intrinsic neutral form [5].
The chemical name for DEM, a direct thrombin inhibitor, is β-Alanine, 
N-[[2-[[[4-[[[(hexyloxy) carbonyl] amino] iminomethyl] phenyl] amino] 
methyl] -1-methyl-1H-benzimidazol-5-yl] carbonyl]-N-2-pyridinyl-ethyl 
ester, methanesulfonate. The empirical formula is C34H41N7O5⋅CH4O3S 
and the molecular weight is 723.86 (mesylate salt), 627.75 (DE - free 
base) and 471.51 (Dabigatran - active moiety), respectively. The structural 
formulae of DEM, DE, and Dabigatran are presented in Figs. 1-3.
There are several processes and degradation impurities of DE, which 
are originated through the synthesis process and degradation during 
storage stability. Even several process impurities and degradation 
impurities of DE reported in prior literature; there are only three main 
degradation impurities of DE. The structure and details of the three 
main impurities A, B, and E are represented in Table 1.
As per literature survey, different assay methods such as UV and HPLC 
were developed for estimation of Dabigatran from finished dosage form 
and bulk API [6,7]. There is no HPLC method specified for determination 
of DE and its related substances in official pharmacopeias (USP 
and European Pharmacopoeia). However, few methods have been 
reported in literature for the determination of DE, and its impurities in 
formulated products which are represented in Table 2.
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ABSTRACTS
Objective: The objective of the study was to develop and validate new, simple, and selective reverse-phase–high-performance liquid chromatography 
(RP-HPLC) method for the quantitative determination of Dabigatran Etexilate (DE) and its impurities in pharmaceutical dosage form as per the 
International Conference on Harmonization guidelines.
Method: Chromatographic analysis was performed on Princeton SPHER-l00 C18 (250 × 4.6 mm, 5 μm) HPLC column, maintained at 50°C column 
temperatures, 6°C sample tray temperature, and detection monitored at 225 nm. The mobile phase consisted of acetonitrile:phosphate buffer (pH 2.5) 
(33:67 V/V). The flow rate was maintained at 1.0 ml/min.
Results: The system suitability results indicate good performance of the system. Specificity study indicates that there is no interference of placebo 
and blank. The percentage relative standard deviation (RSD) of six preparations for known and unknown impurity in the sample solution is found 
below 10%; hence, the method is precise. The calibration curve for DE (unknown impurity), Impurity A was linear from 0.38 to 4.5 μg/ml (correlation 
coefficients [r2] for unknown Impurity [DE] and Impurity A are 0.996 and 0.999, respectively). The calibration curve for Impurity B and Impurity 
E was linear from 0.38 to 9.00 μg/ml (r2 for Impurity B and Impurity E are 0.999 and 0.999, respectively); hence, the method is linear. Accuracy for 
DE (unknown Impurity), Impurity A, Impurity B, and Impurity E are found within 80%–120%; hence, the method is accurate. The percentage RSD 
for a standard solution is found below 5% up to 24 h, and percentage impurity change in the sample solution is found below 0.1% up to 18 h; hence, 
standard solution is stable up to 24 h, and sample solution is stable up to 18 h.
Conclusion: The developed method is new, simple, adequate, specific, precise, linear, and accurate for the determination of DE and its impurities in 
pharmaceutical dosage forms.
Keywords: Dabigatran etexilate, International Conference on Harmonization Guidelines, Reverse-phase–high-performance liquid chromatography, 
Method development, Method validations.
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Fig. 2: Dabigatran etexilate (prodrug)
Fig. 3: Dabigatran (active drug)
Fig. 1: Dabigatran etexilate mesylate (salt)
Table 1: The structure and details of three known impurities A, B, and E
Name of the impurity Structure Type of impurity
Impurity A: Ethyl-3-(2-(((4-Carbamimidoyl phenyl) amino) 
methyl)-l-methyl-N-(pyridin-2-yl)-1H-benzo (d) imidazole-5-carboxamido) 
propanoate
Process related and degradation
Impurity B: 3-(2-(((4-(N’ -((hexyloxy) carbonyl) carbamimidoyl) 
phenyl) amino) methyl)-1-methyl-N -(pyridin-2-yl) -1H-benzo[ d] 
imidazole-5-carboxamido) propanoic acid.
Process related and degradation
Impurity E: Ethyl 3-(2-(((4-(((hexyloxy) carbonyl) carbamoyl) phenyl) amino) 
methyl)-1-methyl N-(pyridin-2-yl) -1 H -benzo [d] imidazole-5-carboxamido) 
propanoate
Process related and degradation
Fig. 4: Chromatogram of blank
Fig. 5: Chromatogram of Dabigatran etexilate standard
Reverse phase liquid chromatography has been proven as a versatile, 
sensitive, reproducible, and highly precise method for its ability to 
separate the complex mixture of drug substances with impurities and 
its easy handling [13]. All these advantages of RP-HPLC make this the 
first choice of modern chemists. Hence, in this scenario, a reproducible 
and accurate method of analysis with properly documented validation 
gives huge support to the pharmaceutical industry. Hence, there is a 
need to develop newer stability indicating method by HPLC to make 
it simple and economical. All the above methods are gradient type RP-
HPLC methods. Hence, it is needed to develop novel, simple, isocratic, 
economic HPLC method for separation of DE and impurities. Hence, 
we proceeded with HPLC method development and validation as per 
International Conference on Harmonization (ICH) guidelines. The 
present analytical work comprises simple, precise, rapid, sensitive, and 
accurate method for the estimation of DE and its known main impurities 
A, B, and E. Therefore, the present work is aimed to develop a new 
and economic method for determination of DE in the pharmaceutical 
formulation in the presence of degradation product. Chromatographic 
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Fig. 6: Chromatogram of placebo
Fig. 8: Chromatogram of Impurity A
Fig. 7: Chromatogram of Dabigatran Etexilate sample
Table 2: Literature review on HPLC methods for determination of DE and its impurities [8-12]
Author and y Eluent 
mode
Column Mobile phase Column 
temperature (°C)
RT (Min) Wavelength
Sandeep et al. Gradient YMC Pack ODS A, 
150*4.6  mm, 5mcg
Mobile phase A: Buffer (potassium 
di hydrogen phosphate) (pH 4.5) 
mobile phase B: Acetonitrile
-- 21.2 220 nm
Dare et al. Gradient Poroshell 120 EC - 18 
 (150 mm×4.6 mm, 2.7μ)
Methanol: Buffer (hexane-1 
sulfonic acid sodium salt 
monohydrate (pH 6.5)
30°C 26.97 230 nm
Nagadeep et al. Gradient Inertsil ODS-3V, 250 mm 
4.6 mm, 5 μm
Mobile phase A: Ammonium 
formate with 0.1% of 
triethylamine (pH 5) mobile phase 
B: Acetonitrile
30°C 36.37 255 nm
Sreenivas et al. Gradient Inertsil ODS-4, 5 m  
(250 mm×4.6 mm)
Mobile phase  
A: Phosphate (potassium 
dihydrogen orthophosphate) 
buffer (pH 3.0) mobile phase B: 
Acetonitrile
25°C 24 220 nm
Ravi Kumar et al. Gradient Inertsil ODS-3 V, 150 
mm×4.6 mm, 5 μm
Mobile phase A: Ammonium 
formate buffer, (pH 4.7) mobile 
phase B: Acetonitrile
35°C 10.17 220 nm
RP-HPLC: Reverse-phase–high-performance liquid chromatography
Fig. 9: Chromatogram of Impurity B
conditions that give the best resolution with minimal elution time 
for the DE and its degradation product. This makes the method to be 
applied in routine work and quantitative determination of the drug and 




DEM (drug) and impurities A, B, and E were provided by ZIM 
Laboratories Limited. All the chemicals and reagents were used in 
HPLC grade. Potassium dihydrogen phosphate (AR grade) was used 
for preparing buffer solution and adjusting the pH to 2.5 with 10% 
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phosphoric acid (AR grade). HPLC grade acetonitrile was used for 
mobile phase preparation.
Instrumental and analytical conditions
Chromatographic analysis was performed on Princeton SPHER-l00 
C18 (250 × 4.6 mm, 5 μm) HPLC column, maintained at 50°C 
column temperatures, 6°C sample tray temperature, and detection 
monitored at 225 nm. The mobile phase used in this analysis 
consists of an Acetonitrile:phosphate buffer (pH 2.5) (33:67 V/V). 
The mobile phase was filtered, degassed before use. The flow rate 
was maintained at 1.0 ml/min. The injector volume of standard and 
sample was 10 μL. The solution was injected, and chromatograms 
were recorded [14]. The optimized chromatographic conditions of 
DE are in Table 3.
Preparation of mobile phase
Preparation of 0.05 M potassium dihydrogen phosphate buffer 
pH 2.5 for mobile phase
Weigh and transfer 6.8 g of potassium dihydrogen phosphate in 1000 ml 
of volumetric flask, add 800 ml of water and sonicate to dissolve for 15 
Table 3: Optimized chromatographic conditions of DE 
parameters
Parameter Solvents
Mobile phase Acetonitrile:phosphate 
buffer (pH 2.5) (33:67 v/v)
Column C18
Diluents Mobile phase (acetonitrile:phosphate 
buffer (pH 2.5) (33:67 v/v)
Column temperature 50°C
Wavelength 225 nm
Injection volume 10 μL




Table 4: System suitability results
S. No RT Area Tailing factor TP
1 26.662 265006 1.063 13174
2 26.632 261320 1.052 13891
3 26.554 265518 1.077 13453
4 26.576 263571 1.063 13718
5 26.52 264489 1.077 13626
Mean±SD 26.5888±0.05773 263981±1652.28
%RSD 0.21714 0.62591
Limit NMT 2% NMT 5%
SD: Standard deviation, %RSD: Percent relative standard deviation
Fig. 11: Overlay chromatograms of blank, placebo, and Dabigatran 
Etexilate sample
Fig. 12: Linearity graph of unknown impurity (Dabigatran 
Etexilate)
Fig. 10: Chromatogram of Impurity E
Fig. 13: Linearity graph of Impurity Area
Fig. 14: Linearity graph of Impurity B
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min, and dilute to volume with water. Adjust pH 2.5 ± 0.05 using dilute 
(10%) phosphoric acid. Filter the solution using a 0.45 μ filter.
Fig. 15: Linearity graph of Impurity E
Table 5: Precision results of Impurity A, B, and E and unknown
S. No Impurity A (%) 
NMT 0.5%
Impurity B (%) 
NMT 1%
Impurity E (%) 
NMT 1%
Highest unknown individual impurity (%) 
NMT 0.5%
Total impurity (%) 
NMT 2.5%
1 0.13 0.58 0.52 0.08 1.10
2 0.12 0.56 0.57 0.08 1.25
3 0.12 0.57 0.53 0.08 1.22
4 0.13 0.57 0.60 0.08 1.30
5 0.13 0.57 0.59 0.07 1.29
6 0.13 0.57 0.60 0.08 1.30
Mean 0.13 0.57 0.57 0.08 1.24
SD 0.0052 0.0063 0.0354 0.0041 0.0771
RSD 4.0 1.1 6.2 5.1 6.2
Limit NMT 10% NMT 10% NMT 10% NMT 10% NMT 10%
SD: Standard deviation, %RSD: Percent relative standard deviation
Table 6: Linearity of unknown Impurity (DE)









DE: Dabigatran Etexilate, LOQ: Limit of quantitation
Table 7: Linearity of Impurity A






Correlation coefficient  
(r2)
0.9995
LOQ: Limit of quantitation
Table 8: Linearity of Impurity B









LOQ: Limit of quantitation
Table 9: Linearity of Impurity E






Correlation coefficient  
(r2)
0.9991
LOQ: Limit of quantitation
Mobile phase
Prepare a filtered and degassed mixture of acetonitrile and buffer pH 
2.5 in the ratio of (33:67 v/v).
Preparation of standard solution
Weigh accurately and transfer DEM working standard (about 87 mg) 
about eq. to 75 mg of DE in 50 ml of volumetric flask, add 25 ml of 
methanol, sonicate to dissolve for 15 min, and dilute to volume with 
methanol. Pipette out 5.0 ml of the resulting solution in 50 ml of 
volumetric flask and dilute to volume with mobile phase. Further, 
pipette out 5.0 ml of the resulting solution in 100 ml of volumetric flask 
and dilute to volume with mobile phase (7.5 µg/ml).
Preparation of sample solution
Weigh and remove the content of 20 capsules, weigh accurately and 
transfer pellets eq. to 300 mg of DE in 200 ml of volumetric flask, add 
50 ml of water, sonicate to dissolve for 10 min, stir the sample solution 
for 30 min by magnetic stirrer, and add about 100 ml of methanol, 
further stir the sample solution for 10 min by magnetic stirrer, and 
dilute to volume with methanol. Centrifuge the resultant solution at 
2000 rpm for 3 min (if required). Pipette out 5.0 ml of the resulting 
solution in 10 ml of a volumetric flask and dilute to volume with 




This method was validated according to ICH guidelines to establish the 
performance characteristics of a method to meet the requirements for 
the intended application of the method. They were tested using the 
optimized chromatographic conditions and instruments.
System suitability
System performance parameters of HPLC method were determined by 
injecting 5 replicate injections of standard solutions. Parameters such 
as retention time, area, tailing factor, and number of theoretical plates 
(N) were determined. From system suitability studies, it is observed 
that percentage relative standard deviation (RSD) values for retention 
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time and area are found within the limit, i.e., not more than 2% and not 
more than 5%, respectively, which indicates good performance of the 
system. System suitability results are tabulated in Table 4.
Specificity
It is the ability to asses explicitly the analyte in the presence of 
components that may be expected to be present. The blank, placebo, 
standard, sample, Impurity A, Impurity B, and Impurity E solution were 
prepared and injected in HPLC system for evaluation of specificity of the 
analytical method.
Observation
The blank and placebo did not show any interference on the retention 
time of DE, Impurity A, Impurity B, and Impurity E in sample 
chromatograms. Hence, it is concluded that analytical method is specific 
for DE, Impurity A, Impurity B, and Impurity E. Typical chromatogram 
of blank, standard, placebo, sample, Impurity A, Impurity B, Impurity 
E, and overlay chromatogram is shown in Figs. 4-11, respectively. It 
revealed that the present analytical RP-HPLC method is specific for DE, 
Impurity A, Impurity B, and Impurity E.
Precision
The precision of the method expresses the closeness of agreement 
between a series of measurements obtained from multiple sampling of 
the same homogeneous sample under prescribed conditions. Precision 
studies were conducted by preparing six different preparations of 
the sample solution, and results are reported in term of RSD. The 
percentage RSD of six preparations for known and unknown impurity 
in the sample solution was found below 10%; hence, method is precise. 
The results are tabulated in Table 5.
Based on the above results, it revealed that the present analytical 
RP-HPLC method is precise for DE (unknown impurity), Impurity A, 
Impurity B, and Impurity E.
Table 10: Accuracy results for unknown Impurity (DE)
Recovery level Area Spiked conc. (μg/ml) Recovered conc.(μg/ml) Recovered (%) Mean recovered (%)
LOQ - 1 14622 0.38 0.410 107.9 107.0
LOQ - 2 13787 0.38 0.390 102.6
LOQ - 3 15107 0.38 0.420 110.5
50% - 1 66543 1.91 1.86 97.4 95.1
50% - 2 64616 1.91 1.80 94.2
50% - 3 64037 1.91 1.79 93.7
100% - 1 137002 3.82 3.83 100.3 102.4
100% - 2 142491 3.82 3.98 104.2
100% - 3 140394 3.82 3.92 102.6
120% - 1 177485 4.59 4.96 108.1 106.9
120% - 2 181911 4.59 5.08 110.7
120% - 3 167722 4.59 4.68 102.0
DE: DE: Dabigatran Etexilate, LOQ: Limit of quantitation
Table 11: Accuracy results for Impurity A
Recovery level Area Spiked conc. (μg/ml) Recovered conc.(μg/ml) Recovered (%) Mean recovered (%)
LOQ - 1 12524 0.35 0.350 100.0 98.1
LOQ - 2 12466 0.35 0.350 100.0
LOQ - 3 11761 0.35 0.330 94.3
50% - 1 63777 1.75 1.79 102.3 102.1
50% - 2 63636 1.75 1.78 101.7
50% - 3 63931 1.75 1.79 102.3
100% - 1 129651 3.51 3.63 103.4 103.3
100% - 2 129646 3.51 3.63 103.4
100% - 3 129457 3.51 3.62 103.1
120% - 1 158246 4.21 4.43 105.2 106.9
120% - 2 168050 4.21 4.70 111.6
120% - 3 156337 4.21 4.38 104.0
LOQ: Limit of quantitation
Table 12: Accuracy results for Impurity B
Recovery level Area Spiked conc. (μg/ml) Recovered conc. (μg/ml) Recovered (%) Mean recovered (%)
LOQ - 1 11110 0.34 0.310 91.2 92.2
LOQ - 2 10870 0.34 0.300 88.2
LOQ - 3 11741 0.34 0.330 97.1
50% - 1 106776 3.37 2.99 88.7 89.2
50% - 2 107522 3.37 3.01 89.3
50% - 3 107865 3.37 3.02 89.6
100% - 1 216495 6.75 6.06 89.8 90.7
100% - 2 220683 6.75 6.18 91.6
100% - 3 218654 6.75 6.12 90.7
120% - 1 257831 8.10 7.22 89.1 91.1
120% - 2 272410 8.10 7.62 94.1
120% - 3 260497 8.10 7.29 90.0
LOQ: Limit of quantitation
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Linearity
A series of solutions was prepared using DE (unknown impurity), 
Impurity A, Impurity B, and Impurity E standard from limit of 
quantitation (LOQ) to 120% of its impurity limits concentration (i.e., 
DE 0.5%, Impurity A 0.5%, Impurity B 1%, and Impurity E 1%). The 
calibration curve for DE (unknown impurity), Impurity A was linear 
from 0.38 to 4.5 μg/ml (r2 for DE=0.996 and 0.999, respectively). The 
calibration curve for Impurity B and Impurity E was also linear from 
0.38 to 9.00 μg/ml (r2 for DE=0.999 and 0.999, respectively). Linearity 
results of DE (unknown impurity), Impurity A, Impurity B, and Impurity 
E are tabulated in Tables 6-9, respectively. Linearity graph of unknown 
Impurity, Impurity A, Impurity B, and Impurity E is represented in 
Figs. 12-15, respectively.
Accuracy
Accuracy solution was prepared in triplicate from LOQ to 120% by 
spiking DE (unknown Impurity), Impurity A, Impurity B, and Impurity 
E of its impurity limits concentration (i.e., DE 0.5%, Impurity A 0.5%, 
Impurity B 1%, and Impurity E 1%). Accuracy is calculated by impurity 
added verses impurities recover. Recovery for DE (unknown Impurity), 
Impurity A, Impurity B, and Impurity E is found within 80% to 120%; 
hence, method is accurate. Accuracy data of unknown Impurity, 
Impurity A, Impurity B, and Impurity E are presented in Tables 10-13, 
respectively.
Solution stability for standard and sample solution
Standard and sample solution was prepared as per method and 
injected at a different interval such as initial, 6 h, 12 h, 18 h, and 24 h. 
The percentage RSD for standard solution is found below 5%, and 
percentage impurity change in the sample solution is found below 
0.1% up to 18 h; hence, standard solution is stable up to 24 h, and 
sample solution is stable up to 18 h. Standard preparation and sample 
preparation solution stability results are presented in Tables 14 and 15, 
respectively.
CONCLUSION
In the present study, the developed method is new, simple, adequate, 
specific, precise, linear, and accurate for the determination of DE and its 
impurities in pharmaceutical dosage forms.
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